<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151931</url>
  </required_header>
  <id_info>
    <org_study_id>SPD405-313</org_study_id>
    <nct_id>NCT00151931</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis</brief_title>
  <official_title>A Multi-Centre, Open-Label Study Assessing the Efficacy and Tolerability of Lanthanum Carbonate in the Reduction of Serum Phosphate Levels in End Stage Renal Disease Patients Receiving Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess phosphate reduction and control in patients with End
      Stage Renal Disease treated with lanthanum carbonate
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-dialysis serum phosphate levels at 3, 5 and 12 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTH, serum calcium and calcium-phosphorus product</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events</measure>
  </secondary_outcome>
  <enrollment>456</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum carbonate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females of childbearing potential agree to take adequate precautions to
             prevent contraception

          -  Patients diagnosed with ESRD must have been receiving a stable dialysis regimen for
             chronic renal failure for the 2 consecutive months prior to enrollment in the study

          -  Patient requires treatment for hyperphosphataemia

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients who continue to require treatment with compounds containing calcium, aluminum
             or magnesium

          -  Patients with clinically significant uncontrolled concurrent illness, a
             life-threatening malignancy or current multiple myeloma

          -  Patients who are HIV+

          -  Patients with any significant gastrointestinal surgery or disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. A Hutchison</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, Manchester Royal Infirmary</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>FDA Recall Information</description>
  </link>
  <link>
    <url>http://www.fosrenol.com/pdf/FOS-00683_FosrenolPI.pdf</url>
    <description>FDA-approved Label</description>
  </link>
  <reference>
    <citation>Hutchison AJ, Laville M; SPD405-313 Lanthanum Study Group. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant. 2008 Nov;23(11):3677-84. doi: 10.1093/ndt/gfn310. Epub 2008 Jun 24.</citation>
    <PMID>18577536</PMID>
  </reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>August 31, 2011</last_update_submitted>
  <last_update_submitted_qc>August 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2011</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

